AFG3L2 Gene Spinocerebellar Ataxia Type 28 Autosomal Dominant Genetic Test
Are you concerned about Spinocerebellar Ataxia Type 28 (SCA28)? DNA Labs UAE offers a comprehensive genetic test for the AFG3L2 gene, which is associated with this neurodegenerative disorder.
Test Details
The AFG3L2 gene is linked to SCA28, a condition characterized by neurodegeneration. SCA28 is an autosomal dominant disorder, meaning that individuals with a mutation in one copy of the AFG3L2 gene will develop the condition.
Our Next-Generation Sequencing (NGS) Genetic Test utilizes advanced sequencing technologies to analyze multiple genes simultaneously. By examining the AFG3L2 gene, our test can identify any genetic mutations or variations that may be causing or predisposing an individual to SCA28.
Components and Price
The cost of the AFG3L2 Gene Spinocerebellar Ataxia Type 28 Autosomal Dominant Genetic Test is AED 4400.0. The test requires a blood sample for analysis.
Report Delivery and Method
Once the sample is received, the report will be delivered within 3 to 4 weeks. Our NGS Technology ensures accurate and efficient analysis of the AFG3L2 gene.
Test Type and Doctor
The AFG3L2 Gene Spinocerebellar Ataxia Type 28 Autosomal Dominant Genetic Test falls under the category of Neurological Disorders. It is recommended to consult with a Neurologist for this test.
Test Department and Pre Test Information
The test is conducted in our Genetics department. Before undergoing the AFG3L2 Gene Spinocerebellar Ataxia Type 28 Autosomal Dominant Genetic Test, it is important to provide the clinical history of the patient. Additionally, a Genetic Counselling session will be conducted to draw a pedigree chart of family members affected by SCA28.
Conclusion
By opting for the AFG3L2 Gene Spinocerebellar Ataxia Type 28 Autosomal Dominant Genetic Test, individuals and their families can gain valuable insights into their genetic makeup. This information can aid in accurate diagnosis, genetic counseling, and potentially explore treatment options for SCA28.
Test Name | AFG3L2 Gene Spinocerebellar ataxia type 28 autosomal dominant Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Neurological Disorders |
Doctor | Neurologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for AFG3L2 Gene Spinocerebellar ataxia type 28, autosomal dominant NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with AFG3L2 Gene Spinocerebellar ataxia type 28, autosomal dominant |
Test Details |
The AFG3L2 gene is associated with a neurodegenerative disorder called Spinocerebellar Ataxia Type 28 (SCA28). SCA28 is an autosomal dominant disorder, meaning that individuals with a mutation in one copy of the AFG3L2 gene will develop the condition. NGS Genetic Test refers to Next-Generation Sequencing Genetic Testing. This type of genetic testing uses advanced sequencing technologies to analyze multiple genes simultaneously and identify genetic mutations or variations that may be associated with a particular disorder, in this case, SCA28. By performing an NGS Genetic Test for the AFG3L2 gene, healthcare professionals can identify any genetic mutations or variations in this gene that may be causing or predisposing an individual to SCA28. This information can be used for accurate diagnosis, genetic counseling, and potential treatment options for affected individuals and their families. |